|Middle East respiratory syndrome|
|Symptoms||Fever, cough, shortness of breath|
|Usual onset||2 to 14 days post exposure|
|Risk factors||Contact with camels and camel products|
|Diagnostic method||rRT-PCR testing|
|Prevention||Hand washing, avoiding contact with camels and camel products|
|Treatment||Symptomatic and supportive|
|Prognosis||34.4% risk of death (all countries)|
|Frequency||2578 cases (as of October 2021)|
Middle East respiratory syndrome (MERS) is a viral respiratory infection caused by Middle East respiratory syndrome–related coronavirus (MERS-CoV). Symptoms may range from none, to mild, to severe. Typical symptoms include fever, cough, diarrhea, and shortness of breath. The disease is typically more severe in those with other health problems.
The first identified case occurred in June 2012 in Jeddah, Saudi Arabia, and most cases have occurred in the Arabian Peninsula. Over 2,500 cases have been reported as of January 2021, including 45 cases in the year 2020. About 35% of those who are diagnosed with the disease die from it. Larger outbreaks have occurred in South Korea in 2015 and in Saudi Arabia in 2018.
MERS-CoV is a coronavirus believed to be originally from bats. However, humans are typically infected from camels, either during direct contact or indirectly. Spread between humans typically requires close contact with an infected person. Its spread is uncommon outside of hospitals. Thus, its risk to the global population is currently deemed to be fairly low. Diagnosis is by rRT-PCR testing of blood and respiratory samples.
As of 2021, there is no specific vaccine or treatment for the disease, but a number are being developed. The World Health Organization (WHO) recommends that those who come in contact with camels wash their hands and not touch sick camels. They also recommend that camel-based food products be appropriately cooked. Treatments that help with the symptoms and support body functioning may be used.
Previous infection with MERS can confer cross-reactive immunity to SARS-CoV-2 and provide partial protection against COVID-19. However, co-infection with SARS-CoV-2 and MERS is possible and could lead to a recombination event.
Signs and symptoms
Early reports compared the viruses to severe acute respiratory syndrome (SARS), and it has been referred to as Saudi Arabia's SARS-like virus. The first person, in June 2012, had a fever, cough, expectoration, and shortness of breath. One review of 47 laboratory confirmed cases in Saudi Arabia gave the most common presenting symptoms as fever in 98%, cough in 83%, shortness of breath in 72% and myalgia in 32% of people. There were also frequent gastrointestinal symptoms with diarrhea in 26%, vomiting in 21%, abdominal pain in 17% of people. 72% of people required mechanical ventilation. There were also 3.3 males for every female. One study of a hospital-based outbreak of MERS had an estimated incubation period of 5.5 days (95% confidence interval 1.9 to 14.7 days). MERS can range from asymptomatic disease to severe pneumonia leading to acute respiratory distress syndrome (ARDS). Kidney failure, disseminated intravascular coagulation (DIC), and pericarditis have also been reported.
Middle East respiratory syndrome is caused by the MERS coronavirus (MERS-CoV), a species with single-stranded RNA belonging to the genus betacoronavirus which is distinct from SARS coronavirus and the common-cold coronavirus. Its genomes are phylogenetically classified into two clades, Clades A and B. Early cases of MERS were of Clade A clusters (EMC/2012 and Jordan-N3/2012) while new cases are genetically different in general (Clade B). The virus grows readily on Vero cells and LLC-MK2 cells. In November 2012, Egyptian virologist Dr. Ali Zaki sent a virus sample from the first confirmed case in Saudi Arabia to virologist Ron Fouchier, a leading coronavirus researcher at the Erasmus Medical Center (EMC) in Rotterdam, the Netherlands. The second laboratory-proven case was in London, confirmed by the UK Health Protection Agency (HPA). The HPA named the virus the London1_novel CoV 2012.
A study performed between 2010 and 2013, in which the incidence of MERS was evaluated in 310 dromedary camels, revealed high titers of neutralizing antibodies to MERS-CoV in the blood serum of these animals. A further study sequenced MERS-CoV from nasal swabs of dromedary camels in Saudi Arabia and found they had sequences identical to previously sequenced human isolates. Some individual camels were also found to have more than one genomic variant in their nasopharynx. There is also a report of a Saudi Arabian man who became ill seven days after applying topical medicine to the noses of several sick camels and later he and one of the camels were found to have identical strains of MERS-CoV. It is still unclear how the virus is transmitted from camels to humans. The World Health Organization advises avoiding contact with camels and to eat only fully cooked camel meat, pasteurized camel milk, and to avoid drinking camel urine. The Saudi Ministry of Agriculture has advised people to avoid contact with camels or wear breathing masks when around them. In response "some people have refused to listen to the government's advice" and kiss their camels in defiance of their government's advice.
There has been evidence of limited, but not sustained spread of MERS-CoV from person to person, both in households as well as in health care settings like hospitals. Most transmission has occurred "in the circumstances of close contact with severely ill persons in healthcare or household settings" and there is no evidence of transmission from asymptomatic cases. Cluster sizes have ranged from 1 to 26 people, with an average of 2.7.
According to World Health Organization, the interim case definition is that a confirmed case is identified in a person with a positive lab test by "molecular diagnostics including either a positive PCR on at least two specific genomic targets or a single positive target with sequencing on a second".
World Health Organization
According to the WHO, a probable case is
- a person with a fever, respiratory infection, and evidence of pneumonia or acute respiratory distress syndrome, where testing for MERS-CoV is unavailable or negative on a single inadequate specimen, and the person has a direct link with a confirmed case.
- A person with an acute febrile respiratory illness with clinical, radiological, or histopathological evidence of pulmonary parenchymal disease (e.g., pneumonia or acute respiratory distress Syndrome), an inconclusive MERS-CoV laboratory test (that is, a positive screening test without confirmation), and a resident of or traveler to Middle Eastern countries where MERS-CoV virus is believed to be circulating in the 14 days before onset of illness.
- A person with an acute febrile respiratory illness of any severity, an inconclusive MERS-CoV laboratory test (that is, a positive screening test without confirmation), and a direct epidemiologic link with a confirmed MERS-CoV case.
Centers for Disease Control
- Fever and pneumonia or acute respiratory distress syndrome (based on clinical or radiological evidence) and either:
- a history of travel from countries in or near the Arabian Peninsula within 14 days before symptom onset, or
- close contact with a symptomatic traveler who developed fever and acute respiratory illness (not necessarily pneumonia) within 14 days after traveling from countries in or near the Arabian Peninsula or
- a member of a cluster of people with severe acute respiratory illness (e.g. fever and pneumonia requiring hospitalization) of unknown cause in which MERS-CoV is being evaluated, in consultation with state and local health departments.
- Fever and symptoms of respiratory illness (not necessarily pneumonia; e.g., cough, shortness of breath) and being in a healthcare facility (as a patient, worker, or visitor) within 14 days before symptom onset in a country or territory in or near the Arabian Peninsula in which recent healthcare-associated cases of MERS have been identified.
- Fever or symptoms of respiratory illness (not necessarily pneumonia; e.g., cough, shortness of breath) and close contact with a confirmed MERS case while the case was ill.
Chest X-ray findings tend to show bilateral patchy infiltrates consistent with viral pneumonitis and acute respiratory distress syndrome (ARDS). Lower lobes tend to be more involved. CT scans show interstitial infiltrates.
MERS cases have been reported to have low white blood cell count, and in particular low lymphocytes. For PCR testing, the World Health Organization (WHO) recommends obtaining samples from the lower respiratory tract via bronchoalveolar lavage (BAL), sputum sample or tracheal aspirate as these have the highest viral loads. There have also been studies utilizing upper respiratory sampling via nasopharyngeal swab.
Several highly sensitive, confirmatory real-time RT-PCR assays exist for rapid identification of MERS-CoV from patient-derived samples. These assays attempt to amplify upE (targets elements upstream of the E gene), open reading frame 1B (targets the ORF1b gene) and open reading frame 1A (targets the ORF1a gene). The WHO recommends the upE target for screening assays as it is highly sensitive. In addition, hemi-nested sequencing amplicons targeting RdRp (present in all coronaviruses) and nucleocapsid (N) gene (specific to MERS-CoV) fragments can be generated for confirmation via sequencing. Reports of potential polymorphisms in the N gene between isolates highlight the necessity for sequence-based characterization.
The WHO recommended testing algorithm is to start with an upE RT-PCR and if positive confirm with ORF 1A assay or RdRp or N gene sequence assay for confirmation. If both an upE and secondary assay are positive it is considered a confirmed case.
Protocols for biologically safe immunofluorescence assays (IFA) have also been developed; however, antibodies against betacoronaviruses are known to cross-react within the genus. This effectively limits their use to confirmatory applications. A more specific protein-microarray based assay has also been developed that did not show any cross-reactivity against population samples and serum known to be positive for other betacoronaviruses. Due to the limited validation done so far with serological assays, WHO guidance is that "cases where the testing laboratory has reported positive serological test results in the absence of PCR testing or sequencing, are considered probable cases of MERS-CoV infection, if they meet the other conditions of that case definition."
While the mechanism of spread of MERS-CoV is currently not known, based on experience with prior coronaviruses, such as SARS, the WHO currently recommends that all individuals coming into contact with MERS suspects should (in addition to standard precautions):
- Wear a medical mask
- Wear eye protection (i.e. goggles or a face shield)
- Wear a clean, non sterile, long sleeved gown; and gloves (some procedures may require sterile gloves)
- Perform hand hygiene before and after contact with the person and his or her surroundings and immediately after removal of personal protective equipment (PPE)
For procedures which carry a risk of aerosolization, such as intubation, the WHO recommends that care providers also:
- Wear a particulate respirator and, when putting on a disposable particulate respirator, always check the seal
- Wear eye protection (i.e. goggles or a face shield)
- Wear a clean, non-sterile, long-sleeved gown and gloves (some of these procedures require sterile gloves)
- Wear an impermeable apron for some procedures with expected high fluid volumes that might penetrate the gown
- Perform procedures in an adequately ventilated room; i.e. minimum of 6 to 12 air changes per hour in facilities with a mechanically ventilated room and at least 60 liters/second/patient in facilities with natural ventilation
- Limit the number of persons present in the room to the absolute minimum required for the person's care and support
- Perform hand hygiene before and after contact with the person and his or her surroundings and after PPE removal.
The duration of infectivity is also unknown so it is unclear how long people must be isolated, but current recommendations are for 24 hours after resolution of symptoms. In the SARS outbreak the virus was not cultured from people after the resolution of their symptoms.
It is believed that the existing SARS research may provide a useful template for developing vaccines and therapeutics against a MERS-CoV infection. As of March 2020 there was one (DNA based) MERS vaccine which completed phase I clinical trials in humans, and three others in progress all of which are viral vectored vaccines, two adenoviral vectored (ChAdOx1-MERS, BVRS-GamVac) and one MVA vectored (MVA-MERS-S).
|WHO total as of Jan 2020||2519||866||34.3%|
|Reported confirmed cases per country|
|United Arab Emirates||74||10||14%|
MERS has had a relatively low population-wide reproduction number in previous outbreaks, but such outbreaks have occurred due to superspreading events. Total laboratory-confirmed cases of MERS world-wide per year have been as follows:
|14||100||381||492||249||250||147||212 (as of 12 Dec)|
MERS was also implicated in an outbreak in April 2014 in Saudi Arabia, where MERS has infected 688 people and 282 MERS-related deaths have been reported since 2012. In response to newly reported cases and deaths, and the resignation of four doctors at Jeddah's King Fahd Hospital who refused to treat MERS patients for fear of infection, the government removed the Minister of Health and set up three MERS treatment centers. Eighteen more cases were reported in early May. In June 2014, Saudi Arabia announced 113 previously unreported cases of MERS, revising the death toll to 282.
A hospital-related outbreak in Riyadh in the summer of 2015 increased fears of an epidemic occurring during the annual Hajj pilgrimage that was to begin in late September. After a period of few cases, cases began increasing in the middle of the summer. The CDC placed the travel health alert to level 2, which calls for taking enhanced precautions.
In May 2019, 14 cases of MERS were reported to the World Health Organisation (WHO) by Saudi authorities, of which five were fatal. All those who died had comorbidities and other relatively serious health problems ranging from only diabetes mellitus in one person (aged 35) to complicated combinations of diabetes mellitus, hypertension and ischemic heart disease in two (65 and 80 years old) and diabetes mellitus, hypertension and nephropathy in another one who was 73 years old. Another patient who died and was 64 years old, had diabetes mellitus and hypertension. All those who died were males and three of them were reported to have had contact with, and exposure to, camels. Among the nine persons who survived were two females who were believed to have had contact with a person infected with MERS, one being a 23-year-old healthcare worker. Of the total 14 cases, four were females and 10 were males. All females survived. Reports of fatal cases were from Riyadh, Jeddah, Madinah and Najran. WHO did not recommend screening of travelers upon arrival or traveling restrictions.
On 2 May 2014, the Centers for Disease Control and Prevention (CDC) confirmed the first diagnosis of MERS in the United States at Community Hospital in Munster, Indiana. The man diagnosed was a health care worker who had been in Saudi Arabia a week earlier, and was reported to be in good condition. A second patient who also traveled from Saudi Arabia was reported in Orlando, Florida on 12 May 2014.
In May 2015, the first case in South Korea was confirmed in a man who had visited Saudi Arabia, United Arab Emirates and Bahrain. Another man from South Korea, who was travelling to China, was diagnosed as the first case in China. So far, no Chinese citizen has been found infected.
In 2018 a case was found in South Korea; the patient had recently returned from Kuwait (via Dubai).
One study found that severe cases of illness had higher viral loads than milder cases, and that concentrations peaked in the second week of illness.
In April 2014, MERS emerged in the Philippines with a suspected case of a home-bound Overseas Filipino Worker (OFW). Several suspected cases involving individuals who were on the same flight as the initial suspected case are being tracked but are believed to have dispersed throughout the country. Another suspected MERS-involved death in Sultan Kudarat province caused the Department of Health (DOH) to put out an alert. On 6 July 2015 the DOH confirmed the second case of MERS in the Philippines. A 36-year-old male foreigner from the Middle East was tested positive.
On 27 July 2015, the accident and emergency department at Manchester Royal Infirmary closed after two patients were treated for suspected MERS infection. The facility was reopened later that evening, and it was later confirmed by Public Health England that the two patients had tested negative for the disease.
In January 2016, a larger outbreak of MERS among camels in Kenya was reported. By 5 February 2016 more than 500 camels had died of the disease. On 12 February 2016, the disease was reported to be MERS. No human cases were identified, although one study found antibodies in healthy humans in Kenya.
|Saudi Arabia outbreak||South Korea outbreak|
|Geographical location||Middle East (Asia)||Far East (Asia)|
|City/province||Riyadh, Jeddah||Seoul, Daejeon, Gyeonggi province|
|Period||11 April – 9 June 2014||4 May – 15 June 2015|
|Overall case number||402||150|
|Health-care personnel (%)||27%||17%|
|Main transmission routes||Health-care center associated||Health-care center associated|
|Previous MERS case before outbreak||Yes||No|
|Types of secondary exposure who were not health-care personnel|
|Admission to health-care facility||34%||30%|
|Visit to patient at health-care facility||17%||29%|
|Annual outpatient department visit (per individual)||4.5||14.6|
|Annual number of hospital admission (per 100 individuals)||10.5||16.1|
The table above provides a comparison between the 2014 Saudi Arabia outbreak and the South Korean outbreak in 2015 of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection.
Collaborative efforts were used in the identification of the MERS-CoV. Egyptian virologist Dr. Ali Mohamed Zaki isolated and identified a previously unknown coronavirus from the lungs of a 60-year-old Saudi Arabian man with pneumonia and acute kidney injury. After routine diagnostics failed to identify the causative agent, Zaki contacted Ron Fouchier, a leading virologist at the Erasmus Medical Center (EMC) in Rotterdam, the Netherlands, for advice. Fouchier sequenced the virus from a sample sent by Zaki.
Fouchier used a broad-spectrum "pan-coronavirus" real-time reverse-transcription polymerase chain reaction (RT-qPCR) method to test for distinguishing features of a number of known coronaviruses (such as OC43, 229R, NL63, and SARS-CoV), as well as for RNA-dependent RNA polymerase (RdRp), a gene conserved in all coronaviruses known to infect humans. While the screens for known coronaviruses were all negative, the RdRp screen was positive.
On 15 September 2012, Dr. Zaki's findings were posted on ProMED-mail, the Program for Monitoring Emerging Diseases, a public health on-line forum.
The United Kingdom's Health Protection Agency (HPA) confirmed the diagnosis of severe respiratory illness associated with a new type of coronavirus in a second patient, a 49-year-old Qatari man who had recently been flown into the UK. He died from an acute, serious respiratory illness in a London hospital. In September 2012, the UK HPA named it the London1 novel CoV/2012 and produced the virus' preliminary phylogenetic tree, the genetic sequence of the virus based on the virus's RNA obtained from the Qatari case.
On 25 September 2012, the WHO announced that it was "engaged in further characterizing the novel coronavirus" and that it had "immediately alerted all its Member States about the virus and has been leading the coordination and providing guidance to health authorities and technical health agencies". The Erasmus Medical Center (EMC) in Rotterdam "tested, sequenced and identified" a sample provided to EMC virologist Ron Fouchier by Ali Mohamed Zaki in November 2012.
On 8 November 2012, in an article published in the New England Journal of Medicine, Dr. Zaki and co-authors from the Erasmus Medical Center published more details, including a tentative name, Human Coronavirus-Erasmus Medical Center (HCoV-EMC), the virus's genetic makeup, and closest relatives (including SARS).
In May 2013, the Coronavirus Study Group of the International Committee on Taxonomy of Viruses adopted the official designation, the Middle East Respiratory Syndrome Coronavirus (MERS-CoV), which was adopted by WHO to "provide uniformity and facilitate communication about the disease". Prior to the designation, WHO had used the non-specific designation 'Novel coronavirus 2012' or simply 'the novel coronavirus'.
When rhesus macaques were given interferon-α2b and ribavirin and exposed to MERS, they developed less pneumonia than control animals. Five critically ill people with MERS in Saudi Arabia with acute respiratory distress syndrome (ARDS) and on ventilators were given interferon-α2b and ribavirin but all ended up dying of the disease. The treatment was started late in their disease (a mean of 19 days after hospital admission) and they had already failed trials of steroids so it remains to be seen whether it may have benefit earlier in the course of disease. Another proposed therapy is inhibition of viral protease or kinase enzymes.
Researchers are investigating a number of medications, including using interferon, chloroquine, chlorpromazine, loperamide, lopinavir, remdesivir and galidesivir as well as other agents such as mycophenolic acid, camostat and nitazoxanide.
- "Middle East respiratory syndrome coronavirus (MERS-CoV)". www.who.int. Retrieved 15 April 2020.
- "MERS Clinical Features". Centers for Disease Control and Prevention. 2 August 2019. Retrieved 16 April 2020.
- "MERS outbreaks". www.emro.who.int. Retrieved 7 February 2021.
- "MERS-CoV | Interim Guidelines for Clinical Specimens from PUI | CDC". www.cdc.gov. 23 March 2020. Retrieved 16 April 2020.
- "Middle East respiratory syndrome (MERS)". nhs.uk. 23 August 2018. Retrieved 15 April 2020.
- Zumla A, Hui DS, Perlman S (September 2015). "Middle East respiratory syndrome". Lancet. 386 (9997): 995–1007. doi:10.1016/S0140-6736(15)60454-8. PMC 4721578. PMID 26049252.
- "Infectious disease outbreaks reported in the Eastern Mediterranean Region in 2018 | News | Epidemic and pandemic diseases". www.emro.who.int. Retrieved 15 April 2020.
- Khan, Anas A.; Alahmari, Ahmed A.; Almuzaini, Yasir; Alamri, Fahad; Alsofayan, Yousef Mohammad; Aburas, Alhanouf; Al-Muhsen, Saleh; Van Kerkhove, Maria; Yezli, Saber; Ciottone, Gregory R.; Assiri, Abdullah M.; Jokhdar, Hani A. (17 September 2021). "Potential Cross-Reactive Immunity to COVID-19 Infection in Individuals With Laboratory-Confirmed MERS-CoV Infection: A National Retrospective Cohort Study From Saudi Arabia". Frontiers in Immunology. 12: 727989. doi:10.3389/fimmu.2021.727989. PMC 8484965. PMID 34603300.
- Buket Baddal and Nedim Cakir (September 2020). "Co-infection of MERS-CoV and SARS-CoV-2 in the same host: A silent threat". Journal of Infection and Public Health. 13 (9): 1251–1252. doi:10.1016/j.jiph.2020.06.017. PMC 7306724. PMID 32622797.
- Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA (November 2012). "Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia". The New England Journal of Medicine. 367 (19): 1814–20. doi:10.1056/NEJMoa1211721. PMID 23075143. S2CID 7671909.
- Doucleef, Michaeleen (26 September 2012). "Scientists Go Deep On Genes Of SARS-Like Virus". NPR. Associated Press. Retrieved 27 September 2012.
- Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, Flemban H, Al-Nassir WN, Balkhy HH, Al-Hakeem RF, Makhdoom HQ, Zumla AI, Memish ZA (September 2013). "Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study". The Lancet. Infectious Diseases. 13 (9): 752–61. doi:10.1016/S1473-3099(13)70204-4. PMC 7185445. PMID 23891402.
- Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, Alabdullatif ZN, Assad M, Almulhim A, Makhdoom H, Madani H, Alhakeem R, Al-Tawfiq JA, Cotten M, Watson SJ, Kellam P, Zumla AI, Memish ZA (August 2013). "Hospital outbreak of Middle East respiratory syndrome coronavirus". The New England Journal of Medicine. 369 (5): 407–16. doi:10.1056/NEJMoa1306742. PMC 4029105. PMID 23782161.
- "Interim Guidance - Clinical management of severe acute respiratory infections when novel coronavirus is suspected: What to do and what not to do" (PDF). WHO. 2 November 2013. Retrieved 21 May 2014.
- Saey, Tina Hesman (2013). "Story one: Scientists race to understand deadly new virus: SARS-like infection causes severe illness, but may not spread quickly among people". Science News. 183 (6): 5–6. doi:10.1002/scin.5591830603. PMC 7169524. PMID 32327842.
- Chu, Daniel K.W.; Poon, Leo L.M.; Gomaa, Mokhtar M.; Shehata, Mahmoud M.; Perera, Ranawaka A.P.M.; Abu Zeid, Dina; El Rifay, Amira S.; Siu, Lewis Y.; Guan, Yi; Webby, Richard J.; Ali, Mohamed A.; Peiris, Malik; Kayali, Ghazi (June 2014). "MERS Coronaviruses in Dromedary Camels, Egypt". Emerging Infectious Diseases. 20 (6): 1049–1053. doi:10.3201/eid2006.140299. PMC 4036765. PMID 24856660.
- "See Also". ProMED-mail. 20 September 2012. Retrieved 31 May 2013.
- Heilprin, John (23 May 2013). "WHO: Probe into deadly coronavirus delayed by sample dispute". CTV News (Canada). Geneva. AP.
- Lu, Guangwen; Liu, Di (2012). "SARS-like virus in the Middle East: A truly bat-related coronavirus causing human diseases". Protein & Cell. 3 (11): 803–805. doi:10.1007/s13238-012-2811-1. PMC 4875465. PMID 23143870.
- "Acute respiratory illness associated with a new virus identified in the UK" (Press release). Health Protection Agency (HPA). 23 September 2012. Archived from the original on 1 February 2014.
- Roos, Robert (25 September 2013). UK agency picks name for new coronavirus isolate (Report). University of Minnesota, Minneapolis, MN: Center for Infectious Disease Research & Policy (CIDRAP).
- Hemida MG, Perera RA, Wang P, Alhammadi MA, Siu LY, Li M, Poon LL, Saif L, Alnaeem A, Peiris M (December 2013). "Middle East Respiratory Syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013". Euro Surveillance. 18 (50): 20659. doi:10.2807/1560-7917.es2013.18.50.20659. PMID 24342517.
- Briese T, Mishra N, Jain K, Zalmout IS, Jabado OJ, Karesh WB, Daszak P, Mohammed OB, Alagaili AN, Lipkin WI (April 2014). "Middle East respiratory syndrome coronavirus quasispecies that include homologues of human isolates revealed through whole-genome analysis and virus cultured from dromedary camels in Saudi Arabia". mBio. 5 (3): e01146-14. doi:10.1128/mBio.01146-14. PMC 4010836. PMID 24781747.
- Gallagher, James (5 June 2014). "Camel infection 'led to Mers death'". BBC News. Retrieved 5 June 2014.
- Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem AM, Madani TA (June 2014). "Evidence for camel-to-human transmission of MERS coronavirus". The New England Journal of Medicine. 370 (26): 2499–505. doi:10.1056/NEJMoa1401505. PMID 24896817. S2CID 40023145.
- "Middle East respiratory syndrome coronavirus (MERS-CoV)". www.who.int. Retrieved 6 April 2020.
- "Mers virus: Saudis warned to wear masks near camels". BBC News. 11 May 2014. Retrieved 22 May 2014.
- "Saudi Arabia: Farmers flout Mers warning by kissing camels". BBC News. 13 May 2014. Retrieved 22 May 2014.
- The Who Mers-Cov Research Group (November 2013). "State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans". PLOS Currents. 5. doi:10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8. PMC 3828229. PMID 24270606.
- "Rapid advice note on home care for patients with Mi ddle East respiratory syndrome coronavirus (MERS-CoV) infecti on presenting with mild symptoms and management of contacts" (PDF). WHO. 8 August 2013. Retrieved 21 May 2014.
- Cauchemez S, Fraser C, Van Kerkhove MD, Donnelly CA, Riley S, Rambaut A, Enouf V, van der Werf S, Ferguson NM (January 2014). "Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility". The Lancet. Infectious Diseases. 14 (1): 50–56. doi:10.1016/S1473-3099(13)70304-9. PMC 3895322. PMID 24239323.
- "Revised interim case definition for reporting to WHO – Middle East respiratory syndrome coronavirus (MERS-CoV)". WHO. 3 July 2013. Archived from the original on 14 June 2013. Retrieved 19 May 2014.
- "Middle East Respiratory Syndrome (MERS): Case definitions". CDC. 9 May 2014. Archived from the original on 27 May 2014. Retrieved 20 May 2014.(an outdated version)
- "Middle East Respiratory Syndrome (MERS): Case definitions". CDC. 10 April 2015. Archived from the original on 27 May 2014. Retrieved 2 June 2015.
- "Laboratory Testing for Middle East Respiratory Syndrome Coronavirus" (PDF). WHO. September 2013. Retrieved 19 May 2014.
- Corman VM, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M, van Boheemen S, Gopal R, Ballhause M, Bestebroer TM, Muth D, Müller MA, Drexler JF, Zambon M, Osterhaus AD, Fouchier RM, Drosten C (September 2012). "Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction". Euro Surveillance. 17 (39). doi:10.2807/ese.17.39.20285-en. PMID 23041020.
- Corman VM, Müller MA, Costabel U, Timm J, Binger T, Meyer B, Kreher P, Lattwein E, Eschbach-Bludau M, Nitsche A, Bleicker T, Landt O, Schweiger B, Drexler JF, Osterhaus AD, Haagmans BL, Dittmer U, Bonin F, Wolff T, Drosten C (December 2012). "Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections". Euro Surveillance. 17 (49). doi:10.2807/ese.17.49.20334-en. PMID 23231891.
- Lu X, Whitaker B, Sakthivel SK, Kamili S, Rose LE, Lowe L, Mohareb E, Elassal EM, Al-sanouri T, Haddadin A, Erdman DD (January 2014). "Real-time reverse transcription-PCR assay panel for Middle East respiratory syndrome coronavirus". Journal of Clinical Microbiology. 52 (1): 67–75. doi:10.1128/JCM.02533-13. PMC 3911421. PMID 24153118.
- Reusken C, Mou H, Godeke GJ, van der Hoek L, Meyer B, Müller MA, Haagmans B, de Sousa R, Schuurman N, Dittmer U, Rottier P, Osterhaus A, Drosten C, Bosch BJ, Koopmans M (April 2013). "Specific serology for emerging human coronaviruses by protein microarray". Euro Surveillance. 18 (14): 20441. doi:10.2807/1560-7917.es2013.18.14.20441. PMID 23594517.
- "Infection prevention and control during health care for probable or confirmed cases of novel coronavirus (nCoV) infection" (PDF). WHO. 5 June 2013. Retrieved 21 May 2014.
- Chan KH, Poon LL, Cheng VC, Guan Y, Hung IF, Kong J, Yam LY, Seto WH, Yuen KY, Peiris JS (February 2004). "Detection of SARS coronavirus in patients with suspected SARS". Emerging Infectious Diseases. 10 (2): 294–9. doi:10.3201/eid1002.030610. PMC 3322905. PMID 15030700.
- Jiang S, Lu L, Du L (2013). "Development of SARS Vaccines and Therapeutics Is Still Needed". Medscape. Retrieved 29 May 2013.
- Butler D (October 2012). "SARS veterans tackle coronavirus". Nature. 490 (7418): 20. Bibcode:2012Natur.490...20B. doi:10.1038/490020a. PMID 23038444.
- Modjarrad, Kayvon; Roberts, Christine C.; Mills, Kristin T.; Castellano, Amy R.; Paolino, Kristopher; Muthumani, Kar; Reuschel, Emma L.; Robb, Merlin L.; Racine, Trina; Oh, Myoung-don; Lamarre, Claude; Zaidi, Faraz I.; Boyer, Jean; Kudchodkar, Sagar B.; Jeong, Moonsup; Darden, Janice M.; Park, Young K.; Scott, Paul T.; Remigio, Celine; Parikh, Ajay P.; Wise, Megan C.; Patel, Ami; Duperret, Elizabeth K.; Kim, Kevin Y.; Choi, Hyeree; White, Scott; Bagarazzi, Mark; May, Jeanine M.; Kane, Deborah; et al. (2019). "Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial". The Lancet Infectious Diseases. 19 (9): 1013–1022. doi:10.1016/S1473-3099(19)30266-X. PMC 7185789. PMID 31351922.
- "Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)". Retrieved 18 March 2020.
- "Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS002)". Retrieved 18 March 2020.
- "Study of Safety and Immunogenicity of BVRS-GamVac". Retrieved 18 March 2020.
- "Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERS-S". Retrieved 18 March 2020.
- Yong, Chean Yeah; Ong, Hui Kian; Yeap, Swee Keong; Ho, Kok Lian; Tan, Wen Siang (2019). "Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus". Frontiers in Microbiology. 10: 1781. doi:10.3389/fmicb.2019.01781. PMC 6688523. PMID 31428074.
- Alshahrani MS, Sindi A, Alshamsi F, Al-Omari A, El Tahan M, Alahmadi B, Zein A, Khatani N, Al-Hameed F, Alamri S, Abdelzaher M, Alghamdi A, Alfousan F, Tash A, Tashkandi W, Alraddadi R, Lewis K, Badawee M, Arabi YM, Fan E, Alhazzani W (January 2018). "Extracorporeal membrane oxygenation for severe Middle East respiratory syndrome coronavirus". Annals of Intensive Care. 8 (1): 3. doi:10.1186/s13613-017-0350-x. PMC 5768582. PMID 29330690.
- Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY (May 2016). "Coronaviruses - drug discovery and therapeutic options". Nature Reviews. Drug Discovery. 15 (5): 327–47. doi:10.1038/nrd.2015.37. PMC 7097181. PMID 26868298.
- "MERS situation update, January 2020". World Health Organization. January 2020.
- "Statistics As of 12 pm June 11, 2015". Command & Control Center, Ministry of Health, Kingdom of Saudi Arabia. 11 June 2015.
- "Last MERS patient died". chosun.com. 25 November 2015.
- "Severe respiratory disease associated with Middle East respiratory syndrome coronavirus (MERS-CoV); Fifteenth update, 8 March 2015" (PDF) (PDF). European Centre for Disease Prevention and Control. 8 March 2015. Archived from the original (PDF) on 27 March 2015. Retrieved 12 March 2015.
- "Middle East respiratory syndrome coronavirus (MERS-CoV) summary and literature update–as of 20 January 2014" (PDF) (PDF). World Health Organization. 20 January 2014. Retrieved 13 May 2014.
- Schnirring L (21 January 2014). "US detects 2nd MERS case; Saudi Arabia has 18 more". Center for Infectious Disease Research and Policy. Retrieved 13 May 2014.
- "Second Dutchman infected with lung virus MERS". NRC Handelsblad. 15 May 2014. Retrieved 17 May 2014.
- "Middle East respiratory syndrome coronavirus (MERS-CoV) – Turkey". World Health Organization. 24 October 2014. Archived from the original on 24 October 2014. Retrieved 26 October 2014.
- "Lebanon Records First Case of MERS Virus". Associated Press. Time. 9 May 2014. Archived from the original on 10 May 2014. Retrieved 10 May 2014.
- "Thailand confirms first case of deadly Mers virus". Bangkok Post. 18 June 2015. Retrieved 20 June 2015.
- Kucharski, Adam; Althaus, Christian L. (2015). "The role of superspreading in Middle East respiratory syndrome coronavirus (MERS-CoV) transmission". Eurosurveillance. 20 (26): 14–8. doi:10.2807/1560-7917.ES2015.20.25.21167. PMID 26132768.
- Epidemic and pandemic-prone diseases Infectious disease outbreaks reported in the Eastern Mediterranean Region in 2018 See 8. Middle East respiratory syndrome (MERS) www.emro.who.int, accessed 29 January 2020
- "Rapid Risk Assessment: Middle East respiratory syndrome coronavirus (MERS-CoV) — Seventeenth update, 11 June 2015" (PDF). European Centre for Disease Prevention and Control. 11 June 2015. Retrieved 12 June 2015.
- MERS-CoV worldwide overview Situation update, 20 December 2020 www.ecdc.europa.eu, accessed 7 February 2020
- McNeil Jr., Donald G. (4 June 2014). "Saudi Arabia: MERS total revised". New York Times. Retrieved 4 June 2014.
- "Saudi reports 2 more deaths from Mers virus, taking toll to 94- Khaleej Times". Khaleej Times. Agence France-Presse. 27 April 2014. Retrieved 4 May 2014.
- McDowall, Angus (27 April 2014). "Saudi Arabia has 26 more cases of MERS virus, 10 dead- Reuters". Reuters. Retrieved 4 May 2014.
- "Another 18 MERS Cases Identified In Saudi Arabia As Disease Spreads". The Huffington Post. Reuters. 8 May 2014. Retrieved 22 May 2014.
- McKenna, Maryn. "MERS Cases Increasing in Saudi Arabia, And The Hajj Is Coming". National Geographic. Retrieved 23 August 2015.
- "Hajj and Umrah in Saudi Arabia". Centers for Disease Control and Prevention. Retrieved 23 August 2015.
- Middle East respiratory syndrome coronavirus (MERS-CoV) – The Kingdom of Saudi Arabia World Health Organisation (WHO) (Official website) Archived Edition (Permanent Link). Retrieved and archived on 19 July 2019
- Excel spreadsheet: 20190626_mers_saudi_arabia.xls World Health Organisation (WHO) (Official website) Archived Edition (Permanent Link) Retrieved and archived on 19 July 2019
- Stobbe, Mike (2 May 2014). "CDC Confirms First Case of MERS in US". ABC News. Archived from the original on 2 May 2014.
- McKay, Betsy (3–4 May 2014). "American Returns from Mideast With MERS Virus". The Wall Street Journal. pp. A3.
- "CDC announces second imported case of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection in the United States" (Press release). CDC. 12 May 2014. Retrieved 12 May 2014.
- Santich, Kate (12 May 2014). "1st MERS case reported in Central Florida". Orlando Sentinel. Retrieved 12 May 2014.
- "1st MERS case reported in the Netherlands". Chicago Tribune. 14 May 2014. Retrieved 14 May 2014.
- Szabo, Liz (2 June 2015). "South Korean MERS outbreak likely to spread, health officials say". USA Today.
- "我国确诊首例输入性MERS病例". Xinhua News Agency (in Chinese). 30 May 2015.
- "MERS forces total sealing off of two hospitals". 12 June 2015.
- Park J, Pomfret J (8 June 2015). "REFILE-UPDATE 2-Hong Kong to issue "red travel alert" to South Korea as MERS spreads". Reuters. (Article published in Eastern Daylight Time)
- "South Korea Reports Third Death as MERS Cases Rise". Wall Street Journal. Retrieved 4 June 2015.
- "14 more MERS cases identified in South Korea". Today Online. 8 June 2015.
- "Fifth Mers death in South Korea". Independent. 7 June 2015.
- "메르스 확진자 23명(이 중 D의료기관 17명) 추가 발생" [MERS infections increased by 23] (in Korean). Korea Ministry of Health and Welfare. 8 June 2015.
- "韩国MERS隔离对象增至2361人 另有560人解除隔离" [Korea increased quarantined objects MERS 2361 and another 560 people who lift the quarantine] (in Chinese). NetEase. 7 June 2015. Archived from the original on 8 June 2015. Retrieved 8 June 2015.
- "South Korea searching for 50 foreigners possibly exposed to Mers". The Straits Times. 11 September 2018. Retrieved 24 January 2020.
- Oh, Myoung-don; Park, Wan Beom; Choe, Pyoeng Gyun; Choi, Su-Jin; Kim, Jong-Il; Chae, Jeesoo; Park, Sung Sup; Kim, Eui-Chong; Oh, Hong Sang; Kim, Eun Jung; Nam, Eun Young; Na, Sun Hee; Kim, Dong Ki; Lee, Sang-Min; Song, Kyoung-Ho; Bang, Ji Hwan; Kim, Eu Suk; Kim, Hong Bin; Park, Sang Won; Kim, Nam Joong (2016). "Viral Load Kinetics of MERS Coronavirus Infection". New England Journal of Medicine. 375 (13): 1303–1305. doi:10.1056/NEJMc1511695. PMID 27682053.
- del Callar, Michaela (24 April 2014). "3 of 5 quarantined Pinoys in UAE tested negative for MERS-CoV- Pinoy Abroad- GMA News Online". GMA Network. Retrieved 4 May 2014.
- Fernandez, Amanda (24 April 2014). "DOH: Only 6 Etihad EY 0424 passengers left who cannot be contacted- News- GMA News Online". GMA Network. Retrieved 4 May 2014.
- "OFWs from UAE quarantined in GenSan, Sarangani for possible MERS infection- MindaNews". MindaNews. 22 April 2014. Retrieved 4 May 2014.
- Lee-Brago, Pia (18 September 2013). "First Pinay dies from MERS virus- Headlines, News, The Philippine Star- philstar.com". The Philippine Star. Retrieved 4 May 2014.
- "DOH confirms MERS case in PH". 6 July 2015.
- "Manchester Royal Infirmary A&E unit closed over virus outbreak". BBC News. 27 July 2015. Retrieved 27 July 2015.
- Glendinning A (28 July 2015). "Two patients in Manchester test negative for MERS virus". men.
- "Mysterious disease kills camels in Marsabit". Daily Nation. 25 January 2016.
- "Anger in the north as mysterious disease wipe out camels". The Star, Kenya.
- "Camels in Kenya test positive for MERS virus". Informer East Africa. Archived from the original on 2 February 2017. Retrieved 16 February 2016.
- "MERS antibody shows promise in rabbits; signs of infection noted in Kenyans". CIDRAP.
- Jack A (June 2015). "Why the panic? South Korea's MERS response questioned". BMJ. 350: h3403. doi:10.1136/bmj.h3403. PMID 26108610. S2CID 38833740.
- Lu G, Liu D (November 2012). "SARS-like virus in the Middle East: a truly bat-related coronavirus causing human diseases". Protein & Cell. 3 (11): 803–5. doi:10.1007/s13238-012-2811-1. PMC 4875465. PMID 23143870.
- Butler, Declan (2013). "Tensions linger over discovery of coronavirus". Nature. doi:10.1038/nature.2012.12108. S2CID 87858299.
- "How threatening is the new coronavirus?". BBC. 24 September 2012. Retrieved 27 September 2012.
- "Novel coronavirus infection" (Press release). WHO. 25 September 2012. Archived from the original on 29 September 2012. Retrieved 27 September 2012.
- "Novel coronavirus update—new virus to be called MERS-CoV" (Press release). WHO. 16 May 2013.
- "Global Alert and Response (GAR): Novel coronavirus infection - update" (Press release). WHO. 23 November 2012. Archived from the original on 27 November 2012.
- Falzarano D, de Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, Brining D, Bushmaker T, Martellaro C, Baseler L, Benecke AG, Katze MG, Munster VJ, Feldmann H (October 2013). "Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques". Nature Medicine. 19 (10): 1313–7. doi:10.1038/nm.3362. PMC 4093902. PMID 24013700.
- Al-Tawfiq JA, Momattin H, Dib J, Memish ZA (March 2014). "Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study". International Journal of Infectious Diseases. 20: 42–6. doi:10.1016/j.ijid.2013.12.003. PMC 7110882. PMID 24406736.
- Spanakis N, Tsiodras S, Haagmans BL, Raj VS, Pontikis K, Koutsoukou A, Koulouris NG, Osterhaus AD, Koopmans MP, Tsakris A (December 2014). "Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen". International Journal of Antimicrobial Agents. 44 (6): 528–32. doi:10.1016/j.ijantimicag.2014.07.026. PMC 7127532. PMID 25288266.
- Ren Z, Yan L, Zhang N, Guo Y, Yang C, Lou Z, Rao Z (April 2013). "The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease". Protein & Cell. 4 (4): 248–50. doi:10.1007/s13238-013-2841-3. PMC 4875521. PMID 23549610.
- Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MR, Frieman MB, Traynor D, Johnson RF, Dyall J, Kuhn JH, Olinger GG, Hensley LE, Jahrling PB (February 2015). "Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis". Antimicrobial Agents and Chemotherapy. 59 (2): 1088–99. doi:10.1128/AAC.03659-14. PMC 4335870. PMID 25487801.
- "Investigating treatment strategies for the Middle East respiratory syndrome coronavirus". The Pharmaceutical Journal. 2014. doi:10.1211/PJ.2014.20066890.
- Cheng KW, Cheng SC, Chen WY, Lin MH, Chuang SJ, Cheng IH, Sun CY, Chou CY (March 2015). "Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus". Antiviral Research. 115: 9–16. doi:10.1016/j.antiviral.2014.12.011. PMC 7113672. PMID 25542975.
- Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY (April 2015). "Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease". Clinical Microbiology Reviews. 28 (2): 465–522. doi:10.1128/CMR.00102-14. PMC 4402954. PMID 25810418.
- Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R, Nunneley JW, Barnard D, Pöhlmann S, McKerrow JH, Renslo AR, Simmons G (April 2015). "Protease inhibitors targeting coronavirus and filovirus entry". Antiviral Research. 116: 76–84. doi:10.1016/j.antiviral.2015.01.011. PMC 4774534. PMID 25666761.
- Báez-Santos YM, St John SE, Mesecar AD (March 2015). "The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds". Antiviral Research. 115: 21–38. doi:10.1016/j.antiviral.2014.12.015. PMC 5896749. PMID 25554382.
- Rabaan AA, Bazzi AM, Al-Ahmed SH, Al-Tawfiq JA (September 2017). "Molecular aspects of MERS-CoV". Front Med. 11 (3): 365–377. doi:10.1007/s11684-017-0521-z. PMC 7089120. PMID 28500431.
- Nash TC, Gallagher TM, Buchmeier MJ (1995). "MHVR-independent cell-cell spread of mouse hepatitis virus infection requires neutral pH fusion". Adv. Exp. Med. Biol. Advances in Experimental Medicine and Biology. 380: 351–7. doi:10.1007/978-1-4615-1899-0_57. ISBN 978-1-4613-5775-9. PMID 8830507.
Media files used on this page
MERS-CoV particles as seen by negative stain electron microscopy. Virions contain characteristic club-like projections emanating from the viral membrane.
Chest X-ray of the first US case of MERS.
MERS-CoV particles as seen by negative stain electron microscopy. Virions contain characteristic club-like projections emanating from the viral membrane.